<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ROXICODONE- oxycodone hydrochloride tablet </strong><br>Mallinckrodt, Inc<br></p></div>
<h1>
<span class="Bold">ROXICODONE<span class="Sup">® </span>CII<br></span><span class="Bold">(Oxycodone Hydrochloride Tablets USP)<br></span><span class="Bold"><br>Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_b47d0586-b56a-4b6b-a103-2ae0e54bb825"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ROXICODONE<span class="Sup">®</span> (oxycodone hydrochloride tablets USP) is an opioid analgesic.</p>
<p>Each tablet for oral administration contains 5 mg, 15 mg or 30 mg of oxycodone hydrochloride USP.</p>
<p>Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. Oxycodone hydrochloride dissolves in water (1 g in 6 to 7 mL) and is considered slightly soluble in alcohol (octanol water partition coefficient is 0.7).</p>
<p>Chemically, oxycodone hydrochloride is 4, 5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride and has the following structural formula:</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a8157d3-ba20-4abf-b0d4-6ad141b31d63&amp;name=roxicodone-1.jpg"></div>
<p>                                                                C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">4</span>•HCl                                             MW 351.82</p>
<p>The 5 mg ROXICODONE<span class="Sup">®</span> tablet contains inactive ingredients: microcrystalline cellulose and stearic acid. The 15 mg and 30 mg tablets contain the following inactive ingredients: microcrystalline cellulose; sodium starch glycolate; corn starch; lactose; stearic acid; D&amp;C Yellow No. 10 (15 mg tablet); and FD&amp;C Blue No. 2 (15 mg and 30 mg tablets).</p>
<p>The 5 mg, 15 mg and 30 mg tablets contain the equivalent of 4.5 mg, 13.5 mg and 27.0 mg, respectively, of oxycodone free base.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_e454346c-d76d-49d2-8136-dd0b4b1c518f"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ef444e13-977a-446d-be43-a8e33754da47"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacology:</h2>
<p class="First">The analgesic ingredient, oxycodone, is a semi-synthetic narcotic with multiple actions qualitatively similar to those of morphine; the most prominent of these involves the central nervous system and organs composed of smooth muscle.</p>
<p>Oxycodone, as the hydrochloride salt, is a pure agonist opioid whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and has been in clinical use since 1917. Like all pure opioid agonists, there is no ceiling effect to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, such as is seen with partial agonists or non-opioid analgesics. Based upon a single-dose, relative-potency study conducted in humans with cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, 10 to 15 mg of oxycodone given intramuscularly produced an <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> similar to 10 mg of morphine given intramuscularly. Both drugs have a 3 to 4 hour duration of action. Oxycodone retains approximately one half of its analgesic activity when administered orally.</p>
<p><span class="Underline">Effects on Central Nervous System</span>: The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of this drug. A significant feature of opioid-induced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is that it occurs without <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. The relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> by morphine-like opioids is relatively selective, in that other sensory modalities, (e.g., touch, vibrations, vision, hearing, etc.) are not obtunded.</p>
<p>Oxycodone produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by direct action on brain stem respiratory centers. The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and to electrical stimulation.</p>
<p>Oxycodone depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla. Antitussive effects may occur with doses lower than those usually required for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Oxycodone causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> may be seen due to <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
<p><span class="Underline">Effects on Gastrointestinal Tract And Other Smooth Muscle</span>: Oxycodone, like other opioid analgesics, produces some degree of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> which is caused by direct stimulation of the chemoreceptor trigger zone (CTZ) located in the medulla. The frequency and severity of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> gradually diminishes with time.</p>
<p>Oxycodone may cause a decrease in the secretion of hydrochloric acid in the stomach that reduces motility while increasing the tone of the antrum, stomach, and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, <span class="product-label-link" type="condition" conceptid="441067" conceptname="Spasm of sphincter of Oddi">spasm of sphincter of Oddi</span>, and transient elevations in serum amylase.</p>
<p><span class="Underline">Effects on Cardiovascular System</span>: Oxycodone, in therapeutic doses, produces <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span> (arteriolar and venous), decreased peripheral resistance, and inhibits baroreceptor reflexes. Manifestations of histamine release and/or <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">peripheral vasodilatation</span> may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and/or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p>Caution should be used in hypovolemic patients, such as those suffering <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, because oxycodone may cause or further aggravate their <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Caution should also be used in patients with <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span> who received therapeutic doses of opioids.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_218c7009-fa1d-444d-ae46-38b7d3531268"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacodynamics:</h2>
<p class="First">The relationship between the plasma level of oxycodone and the analgesic response will depend on the patient’s age, state of health, medical condition and extent of previous opioid treatment.</p>
<p>The minimum effective plasma concentration of oxycodone to achieve <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. Thus, patients need to be treated with individualized titration of dosage to the desired effect. The minimum effective analgesic concentration of oxycodone for any individual patient may increase with repeated dosing due to an increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or development of tolerance.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_b6ea9365-45fa-4c9d-8778-0407551b34a4"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First">The activity of ROXICODONE<span class="Sup">®</span> (oxycodone hydrochloride) tablets is primarily due to the parent drug oxycodone. ROXICODONE<span class="Sup">®</span> tablets are designed to provide immediate release of oxycodone.</p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="7">
<p class="First"><span class="Bold">Table 1</span></p>
<span class="Bold">Pharmacokinetic Parameters (Mean±SD)</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Dose\Parameters</td>
<td class="Botrule Lrule Rrule Toprule" align="center">AUC<br>(ngxhr/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Cmax<br>(ng/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Tmax<br>(hr)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Cmin<br>(ng/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Cavg<br>(ng/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> Half-Life<br>(hr)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Single Dose Pharmacokinetics</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 5 mg tabs x 3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 133.2±33</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 22.3±8.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.8±1.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 3.73±0.9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 15 mg tab</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 128.2±35.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 22.2±7.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.4±0.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.55±1.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> ROXICODONE Liquid Concentrate 15 mg oral solution</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">130.6±34.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21.1±6.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.9±1.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.71±0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 30 mg tab</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 268.2±60.7 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  39.3±14.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  2.6±3.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  3.85±1.3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Food-Effect, Single Dose</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 10 mg/10 mL oral sol’n (fasted)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 105±6.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 19.0±3.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.25±0.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 2.9±0.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 10 mg/10 mL oral sol’n (fed)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 133±25.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 17.7±3.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 2.54±1.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 3.3±0.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Multiple-Dose Studies</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> AUC<br>(72-84)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td></td>
<td> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 5 mg tabs q6h x 14 doses</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 113.3±24.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 15.7±3.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.3±0.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 7.4±1.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 9.4±2.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> ROXICODONE 3.33 mg (3.33 mL) oral sol’n.<br> q4h x 21 doses</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 99.0±24.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12.9±3.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 1.0±0.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 7.2±2.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 9.7±2.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n/a</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Absorption</span>: About 60% to 87% of an oral dose of oxycodone reaches the systemic circulation in comparison to a parenteral dose. This high oral bioavailability (compared to other oral opioids) is due to lower presystemic and/or first-pass metabolism of oxycodone. The relative oral bioavailability of ROXICODONE<span class="Sup">®</span> 15 mg and 30 mg tablets, compared to the 5 mg ROXICODONE<span class="Sup">®</span> tablets, is 96% and 101% respectively. ROXICODONE<span class="Sup">®</span> 15 mg tablets and 30 mg tablets are bioequivalent to the 5 mg ROXICODONE<span class="Sup">®</span> tablet (see Table 1 for pharmacokinetic parameters). Dose proportionality of oxycodone has been established using the ROXICODONE<span class="Sup">®</span> 5 mg tablets at doses of 5 mg, 15 mg (three 5 mg tablets) and 30 mg (six 5 mg tablets) based on extent of absorption (AUC) (see Figure 1). It takes approximately 18 to 24 hours to reach steady-state plasma concentrations of oxycodone with ROXICODONE<span class="Sup">®</span>.</p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a8157d3-ba20-4abf-b0d4-6ad141b31d63&amp;name=roxicodone-2.jpg"></div>
<p><span class="Underline">Food Effect</span>: A single-dose food effect study was conducted in normal volunteers using the 5 mg/5 mL solution. The concurrent intake of a high fat meal was shown to enhance the extent (27% increase in AUC), but not the rate of oxycodone absorption from the oral solution (see Table 1). In addition, food caused a delay in T<span class="Sub">max</span> (1.25 to 2.54 hour). Similar effects of food are expected with the 15 mg and 30 mg tablets.</p>
<p><span class="Underline">Distribution</span>: Following intravenous administration, the volume of distribution (V<span class="Sub">ss</span>) for oxycodone was <br>2.6 L/kg. Plasma protein binding of oxycodone at 37°C and a pH of 7.4 was about 45%. Oxycodone has been found in breast milk (see <span class="Bold"><a href="#LINK_435127ea-4424-4d24-970e-e552896e59e2">PRECAUTIONS-Nursing Mothers</a></span>).</p>
<p><span class="Underline">Metabolism</span>: Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxymorphone, and their glucuronides. The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone. Oxymorphone is present in the plasma only in low concentrations. The analgesic activity profile of other metabolites is not known at present.</p>
<p>The formation of oxymorphone, but not noroxycodone, is mediated by CYP2D6 and as such its formation can, in theory, be affected by other drugs (see <span class="Bold"><a href="#LINK_663cb295-c054-402d-9ce2-0c09dce5fbdd">PRECAUTIONS-Drug Interactions</a></span>).</p>
<p><span class="Underline">Elimination</span>: Oxycodone and its metabolites are excreted primarily via the kidney. The amounts measured in the urine have been reported as follows: free oxycodone up to 19%; conjugated oxycodone up to 50%; free oxymorphone 0%; conjugated oxymorphone ≤ 14%; both free and conjugated noroxycodone have been found in the urine but not quantified. The total plasma clearance was 0.8 L/min for adults. Apparent elimination half-life of oxycodone following the administration of ROXICODONE<span class="Sup">®</span> was 3.5 to 4 hours.</p>
<p><span class="Underline">Special Populations</span>:</p>
<p><span class="Italics">Geriatric:</span> Population pharmacokinetic studies conducted with ROXICODONE<span class="Sup">®</span>, indicated that the plasma concentrations of oxycodone did not appear to be increased in patients over the age of 65.</p>
<p><span class="Italics">Gender:</span> Population pharmacokinetic analyses performed in the clinical study support the lack of gender effect on the pharmacokinetics of oxycodone from ROXICODONE<span class="Sup">®</span>.</p>
<p><span class="Italics">Race:</span> Population pharmacokinetic analyses support the lack of race effect on oxycodone pharmacokinetics after administration of ROXICODONE<span class="Sup">®</span>, but these data <span class="Underline">should be interpreted conservatively</span>, since the majority of patients enrolled into the studies were Caucasians (94%).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> In a clinical trial supporting the development of ROXICODONE<span class="Sup">®</span>, too few patients with decreased renal function were evaluated to study these potential differences. In previous studies, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance &lt; 60 mL/min) had concentrations of oxycodone in the plasma that were higher than in subjects with normal renal function. Based on information available on the metabolism and excretion of oxycodone, dose initiation in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should follow a conservative approach. Dosages should be adjusted according to the clinical situation.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span>:</span> In a clinical trial supporting the development of ROXICODONE<span class="Sup">®</span>, too few patients with decreased hepatic function were evaluated to study these potential differences. However, since oxycodone is extensively metabolized, its clearance may decrease in <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> patients. Dose initiation in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should follow a conservative approach. Dosages should be adjusted according to the clinical situation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_b5ee43bb-9b51-40dc-89ee-890614fb99a4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ROXICODONE<span class="Sup">®</span> tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> where the use of an opioid analgesic is appropriate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_62886e2f-3367-45d1-9ec3-d36af87b5caf"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ROXICODONE<span class="Sup">®</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to oxycodone, or in any situation where opioids are contraindicated. This includes patients with significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>. ROXICODONE<span class="Sup">®</span> is contraindicated in any patient who has or is suspected of having <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_c8f92c57-473c-4573-977d-842a1f0f7f52"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_092cba97-2625-476b-a9d0-491ce7f141a5"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief hazard from all opioid agonist preparations. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.</p>
<p>ROXICODONE<span class="Sup">®</span> should be used with extreme caution in patients with significant <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, and in patients having substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or pre-existing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients, even usual therapeutic doses of ROXICODONE<span class="Sup">®</span> may decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3d3c22ab-ef5b-4ece-b1e3-4cf2b7e0a832"></a><a name="section-5.2"></a><p></p>
<h2>Hypotensive Effect:</h2>
<p class="First">ROXICODONE<span class="Sup">®</span>, like all opioid analgesics, may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in an individual whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone. ROXICODONE<span class="Sup">®</span> may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients. ROXICODONE<span class="Sup">®</span>, like all opioid analgesics, should be administered with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_089e240e-cc75-4a2f-aff4-d13dc6766a69"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>:</h2>
<p class="First">The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_0012f0ed-0765-40cf-bdde-8d8bfbd79611"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_d93ce36b-c259-4496-a277-6f1ceec8c664"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">ROXICODONE<span class="Sup">®</span> tablets are intended for use in patients who require <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span> therapy with an opioid agonist. As with any opioid analgesic, it is critical to adjust the dosing regimen individually for each patient (see <span class="Bold"><a href="#LINK_d181cf53-ecba-4fa0-9672-bf84741d2883">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Selection of patients for treatment with ROXICODONE<span class="Sup">®</span> should be governed by the same principles that apply to the use of other potent opioid analgesics. Opioid analgesics given on a fixed-dosage schedule have a narrow therapeutic index in certain patient populations, especially when combined with other drugs, and should be reserved for cases where the benefits of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> outweigh the known risks of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, altered mental state, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. Physicians should individualize treatment in every case, using nonopioid analgesics, prn opioids and/or combination products, and chronic opioid therapy with drugs such as ROXICODONE<span class="Sup">®</span> (oxycodone hydrochloride) in a progressive plan of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management such as outlined by the World Health Organization, the Agency for Health Care Policy and Research, and the American <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Society.</p>
<p>Use of ROXICODONE<span class="Sup">®</span> is associated with increased potential risks and should be used only with caution in the following conditions: acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>; adrenocortical insufficiency (e.g., Addison’s disease); <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>; <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; debilitated patients; kyphoscoliosis associated with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>; severe impairment of hepatic, pulmonary or renal function; and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p>The administration of ROXICODONE<span class="Sup">®</span>, like all opioid analgesics, may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and all opioids may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1bc1276d-9db9-4088-9fb4-5a03877567be"></a><a name="section-6.2"></a><p></p>
<h2>Tolerance and Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy. Significant tolerance should not occur in most patients treated with the lowest doses of oxycodone. It should be expected, however, that a fraction of patients will develop some degree of tolerance and require progressively higher dosages of ROXICODONE<span class="Sup">®</span> to maintain <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control during chronic treatment. The dosage should be selected according to the patient’s individual analgesic response and ability to tolerate side effects. Tolerance to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of opioids is usually paralleled by tolerance to side effects except for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. </p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> results in withdrawal symptoms in patients who abruptly discontinue the drug or may be precipitated through the administration of drugs with opioid antagonist activity. If ROXICODONE<span class="Sup">®</span> is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur (see <span class="Bold"><a href="#LINK_97015775-19f2-42f8-9f0c-d96a0fa1909f">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). If signs and symptoms of withdrawal occur, patients should be treated by reinstitution of opioid therapy followed by gradual tapered dose reduction of ROXICODONE<span class="Sup">®</span> combined with symptomatic support (see <span class="Bold"><a href="#LINK_1f943e3a-9441-4db2-9bd1-7db1066936ba">DOSAGE AND ADMINISTRATION: Cessation of Therapy</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ce64974c-d1de-4d0b-ad2c-34917c570c5b"></a><a name="section-6.3"></a><p></p>
<h2>Use In Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span>:</h2>
<p class="First">ROXICODONE<span class="Sup">®</span> may cause spasm of the sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Opioids like ROXICODONE<span class="Sup">®</span> may cause increases in the serum amylase level.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_3bea1bc3-1564-4f8a-83ca-a6c9b34feee5"></a><a name="section-6.4"></a><p></p>
<h2>Information for Patients/Caregivers:</h2>
<p class="First">If clinically advisable, patients (or their caregivers) receiving ROXICODONE<span class="Sup">®</span> (oxycodone hydrochloride) tablets should be given the following information by the physician, nurse, pharmacist or caregiver:</p>
<ol class="Arabic">
<li>Patients should be advised to report episodes of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.</li>
<li>Patients should be advised not to adjust the dose of ROXICODONE<span class="Sup">®</span> without consulting the prescribing professional.</li>
<li>Patients should be advised that ROXICODONE<span class="Sup">®</span> may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).</li>
<li>Patients should not combine ROXICODONE<span class="Sup">®</span> with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because additive effects may occur.</li>
<li>Women of childbearing potential who become, or are planning to become pregnant, should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.</li>
<li>Patients should be advised that ROXICODONE<span class="Sup">®</span> is a potential drug of abuse. They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it was prescribed.</li>
<li>Patients should be advised that if they have been receiving treatment with ROXICODONE<span class="Sup">®</span> for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the ROXICODONE<span class="Sup">®</span> dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_663cb295-c054-402d-9ce2-0c09dce5fbdd"></a><a name="section-6.5"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. However, clinicians should be aware of this possible interaction.</p>
<p><span class="Underline">Neuromuscular Blocking Agents</span>: Oxycodone, as well as other opioid analgesics, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.  Review of postmarketing reports has also shown that muscle relaxants, such as cyclobenzaprine, when used with oxycodone may potentially enhance serotonergic activity and result in the development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p><span class="Underline">CNS Depressants</span>: Patients receiving narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with ROXICODONE<span class="Sup">®</span> may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Interactive effects resulting in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may result if these drugs are taken in combination with the usual dosage of ROXICODONE<span class="Sup">®</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
<p><span class="Underline">Mixed Agonist/Antagonist Opioid Analgesics</span>: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) should be administered with caution to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as ROXICODONE<span class="Sup">®</span>. In this situation, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of ROXICODONE<span class="Sup">®</span> and/or may precipitate withdrawal symptoms in these patients.</p>
<p><span class="Underline">Monoamine Oxidase Inhibitors (MAOIs)</span>: MAOIs have been reported to intensify the effects of at least one opioid drug causing <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and significant <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. The use of ROXICODONE<span class="Sup">®</span> is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.  Review of postmarketing reports has also shown that MAOIs, such as phenelzine, when used with oxycodone may potentially enhance serotonergic activity and result in the development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p><span class="Underline">Other Antidepressants (Tricyclic Antidepressant or TCA, Serotonin-Norepinephrine Reuptake Inhibitor or SNRI and Selective Serotonin Reuptake Inhibitor or SSRI:</span> Review of postmarketing reports has shown that other antidepressants, such as TCAs (e.g. doxepine), SSRIs (e.g. fluvoxamine) and SNRIs (e.g. duloxetine and venlafaxine), when used with oxycodone may potentially enhance serotonergic activity and result in the development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_87601d61-1374-4591-8f1e-aedf1aaa85a4"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long-term studies have not been performed in animals to evaluate the carcinogenic potential of ROXICODONE® or oxycodone. The possible effects on male or female fertility have not been studied in animals.</p>
<p>
Oxycodone hydrochloride was genotoxic in an <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay in the presence of metabolic activation. There was no evidence of genotoxic potential in an in vitro bacterial reverse mutation assay <span class="Italics">(<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli)</span> or in an assay for chromosomal aberrations (<span class="Italics">in vivo</span> mouse bone marrow micronucleus assay). 
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_472a7f54-8130-4204-bf90-b0475cac693e"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First"> <span class="Underline">Teratogenic Effects</span>: Category B: Reproduction studies in Sprague-Dawley rats and New Zealand rabbits revealed that when oxycodone was administered orally at doses up to 16 mg/kg (approximately 2 times the daily oral dose of 90 mg for adults on a mg/m<span class="Sup">2</span> basis) and 25 mg/kg (approximately 5 times the daily oral dose of 90 mg on a mg/m<span class="Sup">2</span> basis), respectively was not teratogenic or embryo-fetal toxic. There are no adequate and well controlled studies of oxycodone in pregnant women. Because animal reproductive studies are not always predictive of human responses, ROXICODONE<span class="Sup">®</span> should be used during pregnancy only if potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Underline">Nonteratogenic Effects</span>: Neonates whose mothers have taken oxycodone chronically may exhibit <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or withdrawal symptoms, either at birth and/or in the nursery.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_9cd98e29-0644-42a8-ae66-ef39cd5af717"></a><a name="section-6.8"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">ROXICODONE<span class="Sup">®</span> is not recommended for use in women during or immediately prior to labor. Occasionally, opioid analgesics may prolong labor through actions which temporarily reduce the strength, duration and frequency of uterine contractions. Neonates, whose mothers received opioid analgesics during labor, should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. A specific narcotic antagonist, naloxone, should be available for reversal of narcotic-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_435127ea-4424-4d24-970e-e552896e59e2"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Oxycodone has been detected in breast milk. Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped. Ordinarily, nursing should not be undertaken while a patient is receiving ROXICODONE<span class="Sup">®</span> since oxycodone may be excreted in milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_04905a60-ef06-4617-b5df-28bf338d76a3"></a><a name="section-6.10"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">The safety and efficacy of oxycodone in pediatric patients have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_1b217fff-9a89-4b5c-91c2-7b9c42ecd014"></a><a name="section-6.11"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Of the total number of subjects in clinical studies of ROXICODONE<span class="Sup">®</span>, 20.8% (112/538) were 65 and over, while 7.2% (39/538) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3a3a6cb7-49fc-4005-bca6-b4be9cda35de"></a><a name="section-6.12"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</h2>
<p class="First">Since oxycodone is extensively metabolized, its clearance may decrease in <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> patients. Dose initiation in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should follow a conservative approach. Dosages should be adjusted according to the clinical situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d73be090-b760-4ff5-a716-913fb1ce2a77"></a><a name="section-6.13"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</h2>
<p class="First">Published data reported that elimination of oxycodone was impaired in end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance. Dose initiation should follow a conservative approach. Dosages should be adjusted according to the clinical situation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5c0df727-1a00-4613-8ddc-e70452f0b9e5"></a><a name="section-6.14"></a><p></p>
<h2>Ambulatory Patients:</h2>
<p class="First">ROXICODONE<span class="Sup">®</span> may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_a6e3c14b-ba18-4e09-b5c2-3e25062e1a77"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">ROXICODONE<span class="Sup">®</span> tablets have been evaluated in open label clinical trials in patients with cancer and nonmalignant <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. ROXICODONE<span class="Sup">®</span> tablets are associated with adverse experiences similar to those seen with other opioids.</p>
<p>Serious adverse reactions that may be associated with ROXICODONE<span class="Sup">®</span> therapy in clinical use are those observed with other opioid analgesics and include: <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and/or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (see <span class="Bold"><span class="Bold"><a href="#LINK_8ad34545-ee92-41ba-9aa6-138f99976999">OVERDOSAGE</a></span>, <a href="#LINK_c8f92c57-473c-4573-977d-842a1f0f7f52">WARNINGS</a></span>).</p>
<p>The less severe adverse events seen on initiation of therapy with ROXICODONE<span class="Sup">®</span> are also typical opioid side effects. These events are dose dependent, and their frequency depends on the clinical setting, the patient’s level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. The most frequent of these include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>In many cases the frequency of adverse events during initiation of opioid therapy may be minimized by careful individualization of starting dosage, slow titration and the avoidance of large rapid swings in plasma concentration of the opioid. Many of these adverse events will abate as therapy is continued and some degree of tolerance is developed, but others may be expected to remain throughout therapy.</p>
<p>In all patients for whom dosing information was available (n=191) from the open-label and double-blind studies involving ROXICODONE<span class="Sup">®</span>, the following adverse events were recorded in ROXICODONE<span class="Sup">®</span> treated patients with an incidence ≥ 3%. In descending order of frequency they were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>The following adverse experiences occurred in less than 3% of patients involved in clinical trials with oxycodone:</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Bold">Digestive:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Hemic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</p>
<p><span class="Bold">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>.</p>
<p><span class="Bold">Nervous:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and vasodilation.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
<p><span class="Bold">Skin and Appendages:</span> herpes simplex, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>.</p>
<p><span class="Bold">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p><span class="Bold">Postmarketing Experience:<br></span>Review of postmarketing reports showed the occurrence of the following adverse events:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span><br><span class="Italics">General disorders and administrative site disorders:</span> <span class="product-label-link" type="condition" conceptid="4212326" conceptname="Neonatal Abstinence Syndrome">drug withdrawal syndrome neonatal</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span><br><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span></p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_97015775-19f2-42f8-9f0c-d96a0fa1909f"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_4ba84d63-50a9-4796-9f0b-58b1c161fabb"></a><a name="section-8.1"></a><p></p>
<h2>Controlled Substance:</h2>
<p class="First"><span class="Bold">ROXICODONE<span class="Sup">®</span> contains oxycodone, a mu-agonist opioid of the morphine type and is a Schedule II controlled substance. ROXICODONE<span class="Sup">®</span>, like other opioids used in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, can be abused and is subject to criminal diversion.</span></p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="LINK_d4086575-a6f3-4525-acb7-20688f2336f9"></a><a name="section-8.2"></a><p></p>
<h2>Abuse:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common.</p>
<p>“Drug-seeking? behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss? of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping? to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for nonmedical purposes, often in combination with other psychoactive substances. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p><span class="Bold">ROXICODONE<span class="Sup">®</span> is intended for oral use only. Abuse of ROXICODONE<span class="Sup">®</span> poses a risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The risk is increased with concurrent abuse of alcohol and other substances. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and HIV.</span></p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p><span class="Bold">Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms.</span></p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="LINK_0de45c88-5278-4d93-93b6-9ecb0749b0ed"></a><a name="section-8.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy.</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate. In general, opioids should not be abruptly discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_8ad34545-ee92-41ba-9aa6-138f99976999"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df9cc010-50f2-4d9e-a5d0-3e99c0c7d267"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdose</span> with ROXICODONE<span class="Sup">®</span> can be manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d52f0428-1e1b-46c8-a07d-c9829c2cae17"></a><a name="section-9.2"></a><p></p>
<h2>Treatment:</h2>
<p class="First">To treat ROXICODONE<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>The narcotic antagonists, naloxone or nalmefene, are specific antidotes for opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="Bold">Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to ROXICODONE<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span> If needed the appropriate dose of naloxone hydrochloride or nalmefene should be administered simultaneously with efforts at respiratory resuscitation (see package insert for each drug for the details). Since the duration of action of oxycodone may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Gastric emptying may be useful in removing unabsorbed drug.</p>
<p>Opioid antagonists should be administered cautiously to persons who are suspected to be physically dependent on any opioid agonist, including oxycodone (see <span class="Bold"><a href="#LINK_ea51153b-b920-43f6-aff9-ae0d2f0c1611">Opioid-Tolerant Individuals</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ea51153b-b920-43f6-aff9-ae0d2f0c1611"></a><a name="section-9.3"></a><p></p>
<h2>Opioid-Tolerant Individuals:</h2>
<p class="First"> In an individual physically dependent on opioids, administration of a usual dose of antagonist will precipitate an acute withdrawal. The severity of the withdrawal syndrome produced will depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of the antagonist administered. Use of an opioid antagonist should be reserved for cases where such treatment is clearly needed. If it is necessary to treat serious <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d181cf53-ecba-4fa0-9672-bf84741d2883"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ROXICODONE<span class="Sup">®</span> is intended for the management of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients who require treatment with an oral opioid analgesic. The dose should be individually adjusted according to severity of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, patient response and patient size. If the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> increases in severity, if <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is not adequate, or if tolerance occurs, a gradual increase in dosage may be required.</p>
<p>Patients who have not been receiving opioid analgesics should be started on ROXICODONE<span class="Sup">®</span> in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The dose should be titrated based upon the individual patient’s response to their initial dose of ROXICODONE<span class="Sup">®</span>. Patients with <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> should have their dosage given on an around-the-clock basis to prevent the reoccurrence of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rather than treating the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after it has occurred. This dose can then be adjusted to an acceptable level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> taking into account side effects experienced by the patient.</p>
<p>For control of severe <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span>, ROXICODONE<span class="Sup">®</span> should be administered on a regularly scheduled basis, every 4 to 6 hours, at the lowest dosage level that will achieve adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>As with any potent opioid, it is critical to adjust the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment experience. Although it is not possible to list every condition that is important to the selection of the initial dose of ROXICODONE<span class="Sup">®</span>, attention should be given to: 1) the daily dose, potency, and characteristics of a pure agonist or mixed agonist/antagonist the patient has been taking previously, 2) the reliability of the relative potency estimate to calculate the dose of oxycodone needed, 3) the degree of opioid tolerance, 4) the general condition and medical status of the patient, and 5) the balance between <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and adverse experiences.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1536500c-e43b-4d83-ad21-b04fb0079335"></a><a name="section-10.1"></a><p></p>
<h2>Conversion From Fixed-Ratio Opioid/Acetaminophen, Opioid/Aspirin, or Opioid/Nonsteroidal Combination Drugs:</h2>
<p class="First">When converting patients from fixed ratio opioid/non-opioid drug regimens a decision should be made whether or not to continue the non-opioid analgesic. If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of ROXICODONE<span class="Sup">®</span> in response to the level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and adverse effects afforded by the dosing regimen. If the non-opioid regimen is continued as a separate single entity agent, the starting dose ROXICODONE<span class="Sup">®</span> should be based upon the most recent dose of opioid as a baseline for further titration of oxycodone. Incremental increases should be gauged according to side effects to an acceptable level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0c5f3400-cbe2-4c28-b803-9f0299c3a2de"></a><a name="section-10.2"></a><p></p>
<h2>Patients Currently on Opioid Therapy:</h2>
<p class="First">If a patient has been receiving opioid-containing medications prior to taking ROXICODONE<span class="Sup">®</span>, the potency of the prior opioid relative to oxycodone should be factored into the selection of the total daily dose (TDD) of oxycodone.</p>
<p>In converting patients from other opioids to ROXICODONE<span class="Sup">®</span> close observation and adjustment of dosage based upon the patient’s response to ROXICODONE<span class="Sup">®</span> is imperative. Administration of supplemental <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> for breakthrough or incident <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and titration of the total daily dose of ROXICODONE<span class="Sup">®</span> may be necessary, especially in patients who have disease states that are changing rapidly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_209662a9-8af4-45b6-9736-e02a5686026e"></a><a name="section-10.3"></a><p></p>
<h2>Maintenance of Therapy:</h2>
<p class="First">Continual re-evaluation of the patient receiving ROXICODONE<span class="Sup">®</span> is important, with special attention to the maintenance of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and the relative incidence of side effects associated with therapy. If the level of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> increases, effort should be made to identify the source of increased <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, while adjusting the dose as described above to decrease the level of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>During chronic therapy, especially for non-cancer-related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> associated with other terminal illnesses), the continued need for the use of opioid analgesics should be re-assessed as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1f943e3a-9441-4db2-9bd1-7db1066936ba"></a><a name="section-10.4"></a><p></p>
<h2>Cessation of Therapy:</h2>
<p class="First">When a patient no longer requires therapy with ROXICODONE<span class="Sup">®</span> or other opioid analgesics for the treatment of their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, it is important that therapy be gradually discontinued over time to prevent the development of an opioid abstinence syndrome (narcotic withdrawal). In general, therapy can be decreased by 25% to 50% per day with careful monitoring for signs and symptoms of withdrawal (see <span class="Bold"><a href="#LINK_97015775-19f2-42f8-9f0c-d96a0fa1909f">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span> section for description of the signs and symptoms of withdrawal). If the patient develops these signs or symptoms, the dose should be raised to the previous level and titrated down more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. It is not known at what dose of ROXICODONE<span class="Sup">®</span> that treatment may be discontinued without risk of the opioid abstinence syndrome.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_d3a30ee1-0c50-498e-aa4f-a881c4d86ea3"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f377e68-c99e-445a-bb9f-fd8b87c2303c"></a><a name="section-11.1"></a><p></p>
<h2>ROXICODONE® (oxycodone hydrochloride tablets USP) are available as follows:</h2>
<p class="First"><span class="Bold">5 mg white tablets scored (Identified 54 582)<br></span><span class="Bold">[Embossed 54 582 on one side]<br></span>NDC 23635-580-25: Unit Dose, 25 tablets per card, 4 cards per shipper<br>NDC 23635-580-10: Bottles of 100 tablets</p>
<p><span class="Bold">15 mg green tablets scored (Identified 54 710)<br></span><span class="Bold">[Embossed 54 710 on one side]<br></span>NDC 23635-581-10: Bottles of 100 tablets</p>
<p><span class="Bold">30 mg blue tablets scored (Identified 54 199)<br></span><span class="Bold">[Embossed 54 199 on one side]<br></span>NDC 23635-582-10: Bottles of 100 tablets</p>
<p><span class="Bold">DEA Order Form Required</span></p>
<p>Dispense in a tight, light-resistant container. <br>Protect from moisture.<br>Store at 25°C (77°F); excursions are permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p>Mallinckrodt, the “M? brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.  </p>
<p>© 2014 Mallinckrodt.</p>
<p>Distributed by:<br>Mallinckrodt Brand Pharmaceuticals, Inc. <br>Hazelwood, MO 63042 USA</p>
<p>To request medical information or to report suspected adverse reactions, contact Mallinckrodt at <br>1-800-778-7898.</p>
<p>960B00</p>
<p>Rev 01/2014 </p>
<p><span class="Bold">Mallinckrodt<br>Pharmaceuticals™</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_3782d1d7-d3cb-495f-9623-08daf88cf72a"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg</h1>
<p class="First"><span class="Bold">NDC</span> 23635-580-10</p>
<p>100 Tablets</p>
<p><span class="Bold">ROXICODONE<span class="Sup">®</span><br>Oxycodone Hydrochloride Tablets USP<br></span><span class="Bold">CII</span></p>
<p><span class="Bold">Rx Only </span></p>
<p><span class="Bold">5 mg<br><br></span>See package insert for complete prescribing information.  Store at 25ºC (77ºF) <br>excursions are permitted to 15º-30ºC (59º-86ºF) [See USP Controlled Room Temperature]<br><br>PROTECT FROM MOISTURE<br><br>Dispense in a well-closed container as defined in the USP/NF.</p>
<p>ROXICODONE is a registered trademark of Mallinckrodt LLC.</p>
<p>Distributed by:<br>Mallinckrodt Brand Pharmaceuticals, Inc.<br>Hazelwood, MO 63042 USA</p>
<p><span class="Bold">Mallinckrodt</span> Pharmaceuticals™</p>
<p>1038A-10</p>
<p>Rev 07/2013</p>
<div class="Figure"><img alt="Roxicodone 5mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a8157d3-ba20-4abf-b0d4-6ad141b31d63&amp;name=roxicodone-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7b11faf5-845b-43a8-bab7-dd675ca2cd8e"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 mg</h1>
<p class="First"><span class="Bold">NDC</span> 23635-581-10</p>
<p>100 Tablets</p>
<p><span class="Bold">ROXICODONE<span class="Sup">®</span><br>Oxycodone Hydrochloride Tablets USP<br></span><span class="Bold">CII</span></p>
<p><span class="Bold">Rx Only </span></p>
<p><span class="Bold">15 mg<br><br></span>See package insert for complete prescribing information.  Store at 25ºC (77ºF) <br>excursions are permitted to 15º-30ºC (59º-86ºF) [See USP Controlled Room Temperature]<br><br>PROTECT FROM MOISTURE<br><br>Dispense in a well-closed container as defined in the USP/NF.</p>
<p>ROXICODONE is a registered trademark of Mallinckrodt LLC.</p>
<p>Distributed by:<br>Mallinckrodt Brand Pharmaceuticals, Inc.<br>Hazelwood, MO 63042 USA</p>
<p><span class="Bold">Mallinckrodt</span> Pharmaceuticals™</p>
<p>960B10<br>Rev 08/2012</p>
<div class="Figure"><img alt="Roxicodone 15mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a8157d3-ba20-4abf-b0d4-6ad141b31d63&amp;name=roxicodone-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_50695477-26b2-429f-af48-22ca76a550b1"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 mg</h1>
<p class="First"><span class="Bold">NDC</span> 23635-582-10</p>
<p>100 Tablets</p>
<p><span class="Bold">ROXICODONE<span class="Sup">®</span><br>Oxycodone Hydrochloride Tablets USP<br></span><span class="Bold">CII</span></p>
<p><span class="Bold">Rx Only </span></p>
<p><span class="Bold">30 mg<br><br></span>See package insert for complete prescribing information.  Store at 25ºC (77ºF) <br>excursions are permitted to 15º-30ºC (59º-86ºF) [See USP Controlled Room Temperature]<br><br>PROTECT FROM MOISTURE<br><br>Dispense in a well-closed container as defined in the USP/NF.</p>
<p>ROXICODONE is a registered trademark of Mallinckrodt LLC.</p>
<p>Distributed by:<br>Mallinckrodt Brand Pharmaceuticals, Inc.<br>Hazelwood, MO 63042 USA</p>
<p><span class="Bold">Mallinckrodt</span> Pharmaceuticals™</p>
<p>961B10<br>Rev 08/2012</p>
<div class="Figure"><img alt="Roxicodone 30mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a8157d3-ba20-4abf-b0d4-6ad141b31d63&amp;name=roxicodone-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROXICODONE 		
					</strong><br><span class="contentTableReg">oxycodone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23635-580</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYCODONE HYDROCHLORIDE</strong> (OXYCODONE) </td>
<td class="formItem">OXYCODONE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;582</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23635-580-25</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">25  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:23635-580-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021011</td>
<td class="formItem">08/26/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROXICODONE 		
					</strong><br><span class="contentTableReg">oxycodone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23635-581</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYCODONE HYDROCHLORIDE</strong> (OXYCODONE) </td>
<td class="formItem">OXYCODONE HYDROCHLORIDE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (GREEN) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;710</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23635-581-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021011</td>
<td class="formItem">08/31/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROXICODONE 		
					</strong><br><span class="contentTableReg">oxycodone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23635-582</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYCODONE HYDROCHLORIDE</strong> (OXYCODONE) </td>
<td class="formItem">OXYCODONE HYDROCHLORIDE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;199</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23635-582-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021011</td>
<td class="formItem">08/31/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mallinckrodt, Inc
							(047021092)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4167cddf-ba9e-41e2-ade0-c14ccd40d8fa</div>
<div>Set id: 5a8157d3-ba20-4abf-b0d4-6ad141b31d63</div>
<div>Version: 4</div>
<div>Effective Time: 20140130</div>
</div>
</div> <div class="DistributorName">Mallinckrodt, Inc</div></p>
</body></html>
